The 29 portfolio companies we’ve helped build have attracted more than $2.3B of risk capital, employ close to 1,000 Canadians and have a combined value of $4B.
Encycle Therapeutics was created to develop a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. The company was acquired by Zealand Pharma in 2019.